Evidence map›Paper›PMID 33413350›Full record

Observational studyBMC medical genomics2021

The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder.

Jessica Heil, Stefan Zajic, Emily Albertson, Andrew Brangan, Iris Jones, Wendy Roberts, Michael Sabia, Elliot Bodofsky, Alissa Resch, Rachel Rafeq and 6 more

Abstract readObservational Study
In one paragraph

Observational study in BMC medical genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jessica HeilCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA. heil-jessica1@cooperhealth.edu.ORCID 0000-0002-8876-0922
Stefan ZajicCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
Emily AlbertsonCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
Andrew BranganCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
Iris JonesCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Wendy RobertsCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
Michael SabiaCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Elliot BodofskyCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Alissa ReschCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
Rachel RafeqCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Rachel HarozCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Russell BuonoRowan University, 201 Mullica Hill Rd, Glassboro, NJ, 08028, USA.
Thomas N FerraroRowan University, 201 Mullica Hill Rd, Glassboro, NJ, 08028, USA.
Laura ScheinfeldtCoriell Institute for Medical Research, 403 Haddon Ave, Camden, NJ, 08103, USA.
Matthew SalzmanCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.
Kaitlan BastonCooper University Health Care, 1 Cooper Plaza, Camden, NJ, 08103, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe opioid use disorder and overdose crisis in the United States affects public health as well as social and economic welfare. While several genetic and non-genetic risk factors for opioid use disorder have been identified, many of the genetic associations have not been independently replicated, and it is not well understood how these factors interact. This study is designed to evaluate relationships among these factors prospectively to develop future interventions to help prevent or treat opioid use disorder.

methodsThe Genomics of Opioid Addiction Longitudinal Study (GOALS) is a prospective observational study assessing the interplay of genetic and non-genetic by collecting comprehensive genetic and non-genetic information on 400 participants receiving medication for opioid use disorder. Participants will be assessed at four time points over 1 year. A saliva sample will be collected for large-scale genetic data analyses. Non-genetic assessments include validated surveys measuring addiction severity, depression, anxiety, and adverse childhood experiences, as well as treatment outcomes such as urine toxicology results, visit frequency, and number of pre and post-treatment overdoses extracted from electronic medical records. DISCUSSION: We will use these complex data to investigate the relative contributions of genetic and non-genetic risk factors to opioid use disorder and related treatment outcomes.

Indexed as

GenomicsOpioid-Related DisordersAdultFemaleHumansLongitudinal StudiesMaleProspective StudiesResearch DesignRisk FactorsAddictionBuprenorphineGeneticsMedication for opioid use disorder (MOUD)Opioid use disorder (OUD)Substance misuse

Identifiers

PMID33413350
PMCPMC7792024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.